Chief MD, Gangnam
Duk-ha Kim
The trust our patients have placed in this clinic was built on conviction and principle. We intend to hold to both, unchanged, through the next hundred years.
Seoul
Hyaluronic-acid injectable guide
Belotero Revive is an absorbable injectable implant containing non-animal cross-linked sodium hyaluronate 20 mg/mL and glycerol 17.5 mg/mL. The source used here is a Thailand instructions-for-use document for early photoaged facial skin; it does not establish a Korean approval or indication.
Belotero Revive is described in the Merz Thailand instructions for use as a sterile, viscoelastic and absorbable injectable implant. It combines cross-linked sodium hyaluronate of non-animal origin with glycerol; that product identity should not be expanded into claims for every injectable sold as a skin booster.

Sources: Merz Aesthetics — BELOTERO Revive instructions for use (Thailand, 30 August 2024)
The Thailand IFU lists cross-linked sodium hyaluronate at 20 mg/mL and glycerol at 17.5 mg/mL. These are composition facts, not proof that every person will obtain a particular degree of hydration, elasticity or line improvement.
Sources: Merz Aesthetics — BELOTERO Revive instructions for use (Thailand, 30 August 2024)
The cited IFU addresses implantation into facial skin showing early signs of photodamage, with hydration, elasticity and superficial fine lines named in its intended scope. It is a market-specific document and cannot be presented as the Korean indication.
Sources: Merz Aesthetics — BELOTERO Revive instructions for use (Thailand, 30 August 2024)
No. A Thailand IFU can identify the product and describe the wording used in that market, but it does not prove Korean authorization, a Korean indication or the exact product supplied by a clinic in Korea. Confirm the Korean-distributed box, model and local instructions before treatment.
Sources: Merz Aesthetics — BELOTERO Revive instructions for use (Thailand, 30 August 2024)
No. The FDA page cited here is general patient safety information about dermal fillers; it is not a Belotero Revive approval record. It is used only to explain class-level injection risks and must not be converted into an FDA approval claim for this product.
Neither source cited on this page states a duration for this specific product, so what follows is what generally decides how long a cross-linked hyaluronic acid implant is present in the skin: the concentration and degree of cross-linking of the material, the depth and area it is placed in, and each person’s own rate of breaking it down. None of those factors are quantified for Belotero Revive in the sources used here, so ask the clinic what it is basing any stated timeline on, and how a repeat session would be decided, rather than treating an advertised figure as established fact.
Sources: Merz Aesthetics — BELOTERO Revive instructions for use (Thailand, 30 August 2024)U.S. FDA — Dermal Fillers (Soft Tissue Fillers)
The FDA lists common filler reactions such as bruising, redness, swelling, pain, tenderness, itching and rash, as well as less common nodules and infection. The product IFU must also be reviewed because product-specific contraindications, warnings and handling instructions cannot be replaced by a general web summary.
Sources: U.S. FDA — Dermal Fillers (Soft Tissue Fillers)Merz Aesthetics — BELOTERO Revive instructions for use (Thailand, 30 August 2024)
Accidental injection into a blood vessel can cause tissue death and, rarely, vision abnormalities including blindness or stroke. Unusual pain, blanching or discolouration, visual change, or neurological symptoms during or soon after injection require immediate medical assessment rather than routine follow-up.
These two sources do not justify one fixed duration, interval or session count for everyone. A clinic plan should be based on the locally supplied product information, the treatment area and individual assessment; an advertised timetable is not a guaranteed outcome.
Sources: Merz Aesthetics — BELOTERO Revive instructions for use (Thailand, 30 August 2024)U.S. FDA — Dermal Fillers (Soft Tissue Fillers)
Ask for the full product name, outer box and lot, the Korean-distributed instructions, the planned area and injection route, and the clinician responsible for complications. Also ask how urgent symptoms are handled after you leave Korea, because delayed or vascular problems need a clear contact route.
Sources: Merz Aesthetics — BELOTERO Revive instructions for use (Thailand, 30 August 2024)U.S. FDA — Dermal Fillers (Soft Tissue Fillers)
Care is provided by the medical team at the branch you select. These clinicians lead the three branches linked from this guide; confirm the doctor assigned to your visit with that branch.
Chief MD, Gangnam
The trust our patients have placed in this clinic was built on conviction and principle. We intend to hold to both, unchanged, through the next hundred years.
Chief MD, Myeongdong
I want to be thinking about how the patient feels right up to the last moment of the procedure.
Chief MD, Hongdae
I will give my best with the attentiveness to catch even the smallest change.
Listed branch medical team — not a medical-review byline for this article.
Yes. The Thailand IFU identifies cross-linked sodium hyaluronate of non-animal origin at 20 mg/mL.
The cited Thailand IFU lists glycerol at 17.5 mg/mL.
Yes. The IFU describes it as an absorbable injectable implant; that is a product classification, not a promise about an exact personal timeline.
The Thailand document refers to early photoaged facial skin and names hydration, elasticity and superficial fine lines within its intended scope.
No. It is useful evidence about the product in Thailand, but it does not establish Korean approval or a Korean indication.
This page makes no such claim. The cited FDA source is a general dermal-filler safety page, not a product approval record.
No permanent-effect claim is supported here. The IFU describes an absorbable implant, and individual outcomes should not be stated as permanent.
The cited sources do not support one session count for everyone. The plan must be discussed after checking the local product information and the treatment area.
No universal interval is stated here. A fixed timetable should not be presented as a regulatory fact or guaranteed protocol.
The two cited sources do not justify a fixed duration for every person. Avoid treating a clinic estimate as a guarantee.
The FDA lists bruising, redness, swelling, pain, tenderness, itching and rash among reported reactions to dermal fillers generally.
Yes. The FDA warns that unintended blood-vessel injection can cause tissue death and, rarely, blindness or stroke.
Check the full product name, sealed box, lot, Korean-distributed instructions, planned area and the clinic contact for urgent or delayed concerns.
No universal-suitability claim is appropriate. Eligibility requires review of the product-specific IFU, medical history, previous injections and the planned treatment area.
We started in Gangnam in 2006 and the network now runs 17 branches across Korea. The line we work to is skin transformation woven into everyday life — care you can keep up with, rather than one dramatic change.
Free Consultation
There is no inquiry form on this page. Once you have picked a branch above, open that branch’s site or the official reservation center and choose a time yourself.